LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 1.74 USD Market Closed
Market Cap: 45.8m USD
Section:
 

Relative Value

The Relative Value of one LVTX stock under the Base Case scenario is 2.52 USD. Compared to the current market price of 1.74 USD, LAVA Therapeutics NV is Undervalued by 31%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LVTX Relative Value
Base Case
2.52 USD
Undervaluation 31%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.8
P/S
P/S
Price to Sales
3.8
vs History
57
vs Industry
63
Median 3Y
3.8
Median 5Y
4.8
Industry
7.9
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-1.2
Median 5Y
-1.5
Industry
24
Forward
-2
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
10
Median 3Y
-1.8
Median 5Y
-2.9
Industry
21.6
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
8
Median 3Y
-1.8
Median 5Y
-2.9
Industry
23.7
More Details
2.3
P/B
P/B
Price to Book Value
2.3
vs History
1
vs Industry
59
Median 3Y
1.2
Median 5Y
1.2
Industry
3.4
More Details
Negative
EV/S
EV/S
Enterprise Value to Sales
N/A
vs History
vs Industry
74
Median 3Y
-2.8
Median 5Y
-2.7
Industry
8.3
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
68
Median 3Y
-19.6
Median 5Y
0
Industry
10.3
More Details
0.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
0.2
vs History
67
vs Industry
17
Median 3Y
1.1
Median 5Y
0.6
Industry
6.7
Forward
0.3
More Details
0.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
0.2
vs History
67
vs Industry
15
Median 3Y
1
Median 5Y
0.6
Industry
7.2
Forward
0.4
More Details
0.7
EV/OCF
EV/OCF
Enterprise Value to OCF
0.7
vs History
45
vs Industry
19
Median 3Y
0.9
Median 5Y
0.4
Industry
8.2
More Details
0.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
0.7
vs History
45
vs Industry
15
Median 3Y
0.9
Median 5Y
0.4
Industry
6.7
More Details
Negative
EV/IC
EV/IC
Enterprise Value to IC
N/A
vs History
vs Industry
32
Median 3Y
-10.7
Median 5Y
-6.4
Industry
5.7
More Details

Multiples Across Competitors

LVTX Competitors Multiples
LAVA Therapeutics NV Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
NL
LAVA Therapeutics NV
NASDAQ:LVTX
45.8m USD 3.8 -0.9 0.2 0.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 111 463.2 -162 126.7 -196 873.6 -194 627
US
Abbvie Inc
NYSE:ABBV
397B USD 6.7 169.1 16.4 23.2
US
Amgen Inc
NASDAQ:AMGN
170.3B USD 4.7 24.3 17.7 17.7
US
Gilead Sciences Inc
NASDAQ:GILD
149.6B USD 5.1 18.4 12.4 12.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
111.4B USD 9.5 30.3 22.2 23.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 065.3 -527 -573.9 -558.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
75.5B USD 5.3 16.5 15.6 17.7
AU
CSL Ltd
ASX:CSL
87.9B AUD 3.8 19.5 13.1 16.3
NL
argenx SE
XBRU:ARGX
47B EUR 15.2 35.7 61.8 63.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
54B USD 16.8 1 239.6 163 197.7
P/S Multiple
Revenue Growth P/S to Growth
NL
LAVA Therapeutics NV
NASDAQ:LVTX
Average P/S: 3 101 236.3
3.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
34 111 463.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.7
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
5%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
5.1
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.5
10%
0.9
US
E
Epizyme Inc
F:EPE
2 065.3
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.3
6%
0.9
AU
CSL Ltd
ASX:CSL
3.8
5%
0.8
NL
argenx SE
XBRU:ARGX
15.2
49%
0.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.8
46%
0.4
P/E Multiple
Earnings Growth PEG
NL
LAVA Therapeutics NV
NASDAQ:LVTX
Average P/E: 194.2
Negative Multiple: -0.9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 126.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
169.1
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.3
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.4
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.3
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
9%
1.8
AU
CSL Ltd
ASX:CSL
19.5
11%
1.8
NL
argenx SE
XBRU:ARGX
35.7
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 239.6
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NL
LAVA Therapeutics NV
NASDAQ:LVTX
Average EV/EBITDA: 35.8
0.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 873.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.4
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.7
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.2
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -573.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.6
11%
1.4
AU
CSL Ltd
ASX:CSL
13.1
8%
1.6
NL
argenx SE
XBRU:ARGX
61.8
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
163
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NL
LAVA Therapeutics NV
NASDAQ:LVTX
Average EV/EBIT: 41.3
0.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 627 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.7
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.4
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.2
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -558.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
13%
1.4
AU
CSL Ltd
ASX:CSL
16.3
11%
1.5
NL
argenx SE
XBRU:ARGX
63.5
N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
197.7
N/A N/A

See Also

Summary
LVTX intrinsic value, competitors valuation, and company profile.
DCF Valuation
LVTX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LVTX stock valuation using valuation multiples.
Wall Street Estimates
LVTX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LVTX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 302,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.